SNIPR announces grant of patent by the European Patent Office protecting the newly-discovered and characterised CRISPR-CasS system
This system and its uses do not rely on Cas9 or Cas3. The patent covers use of the new CasS system in both prokaryotic and eukaryotic cells, as well as when fused to effector domains conferring additional functionality, such as base editors and nuclease domains. Commercial licenses are available.